Importantly, though, with our PCLS and in situ data, we cannot distinguish whether the ZEB1-dependent CTL abundance (in situ) and the CCR2/CCR4-dependent tumor control (PCLS) are regulated by a direct recruitment of CD8 + T cells by CCL2 and/or CCL22 or other alternative mechanisms. The gene discussed is CCR2; the disease is neoplasm.